Innovative Technologies for Stratified and Experimental Medicine

Lead Research Organisation: University of Cambridge
Department Name: Clinical School

Abstract

We aim to build scientific and computing infrastructure in the School of Clinical Medicine at the University of Cambridge that will allow us i) to develop new technologies for measuring and imaging molecules in humans, and ii) to apply these technologies directly and immediately to major research programmes for understanding and treatment of cancer, metabolic disorders, and many other therapeutic areas.

Our strategic vision is that many diseases, that are traditionally diagnosed and treated as if all patients with the same diagnosis were largely the same, will become increasingly stratified. We expect that advances in biomedical science will demonstrate that there are in fact many different genetic and molecular pathways to the same clinical diagnosis. This has potentially important implications for more precise targeting of treatment: more refined diagnostic stratification of patients could identify more exactly which patients were most likely to respond to specific treatments. To realise this vision, we propose to create three new high-tech facilities for clinical research in Cambridge; a Stratified Medicine Core Laboratory (SMCL), a Molecular Imaging Centre (MIC), and a High Performance Hub for Informatics (HPHI).

The SMCL will allow us to measure a large number of peptides and other molecules in blood or other tissue samples with enhanced accuracy and sensitivity. The SMCL will also provide new facilities for next generation sequencing of DNA so that genetic variants driving disease can be identified in individual patients with sufficient precision and reliability to optimize diagnostic stratification and to inform clinical management immediately.

The MIC will allow us to measure molecules by imaging of patients, rather than by lab analysis of tissue samples. The MIC will comprise a new whole body scanner that can simultaneously collect MRI and PET data, as well as new facilities for manufacturing and administering labeled molecules as imaging probes to patients. The new radiochemistry facilities in the MIC will allow us to produce a much larger range and volume of radioactively labeled molecules that can be detected by PET imaging. The MIC will also support the technological development of dynamic nuclear polarization (DNP). This is a radically innovative method of molecular imaging which could potentially allow us to detect labeled molecules by MRI and without exposing patients to the risks of radioactivity. We will also upgrade one of our existing MRI scanners and locate it closer to the main focus of experimental medicine research in Cambridge.

The HPHI will provide the computational resources required to store and analyse the very large volumes of data produced by the SMCL and the MIC. It is also crucially important that the results of clinically actionable molecular analysis and imaging can be linked to individual patient records. This is key to "pulling through" the benefits of new technology to deliver stratified medicine in clinical practice. It is also important that the "big data" generated by the SMCL and MIC can be shared with the wider scientific community including our research partners elsewhere in the UK. We therefore propose to invest in new facilities for data storage, computational analysis, secure and ethically approved linkage of research data to clinical records, and data sharing. This computational hub will be managed as part of the University of Cambridge's new high performance computing facility.

These infrastructural investments have been planned to create an integrated platform for molecular and genetic stratification of human disease. They will enhance the impact of internationally leading research groups already established in Cambridge and they are coordinated with major infrastructural programmes already funded by the University or other agencies. They will underpin a step change in our capacity to harness the potential of new technologies to deliver our strategic vision.

Technical Summary

The vision is to use the explanatory and predictive power of genetics, biomolecular assays, and molecular imaging, to refine diagnostic and therapeutic stratification of patients with cancer, metabolic, neuroscience, cardiovascular and musculoskeletal disorders. To do this, we are seeking capital investment in 3 coordinated and strategically important areas for innovative technology and stratified medicine in Cambridge:
1) Stratified Medicine Core Laboratory: will deliver high-throughput, clinically actionable, sensitive and precise measures of multiple pathophysiologically important biomolecules. The SMCL will use new mass spectrometry immuno-assays for a wide range of peptides; extended capacity for existing multiplex assays; and next generation sequencing for deep genotyping.
2) Molecular Imaging Centre: will pioneer clinical translation of new technologies, such as dynamic nuclear polarization imaging and simultaneous PET/MRI imaging of radioligand binding (PET) combined with MRI markers of local tissue structure and function. The MIC will provide pharmacy support for quality controlled production and administration of PET radioligands and hyperpolarized molecules for DPN imaging. It will also include some enhanced capacity for 3T MRI in stratified and experimental medicine, optical imaging of epithelial dysplasia and neoplasia, and cell tracking in regenerative medicine.
3) High Performance Hub for Informatics: will deliver storage, analysis, sharing, and NHS clinical linkage, for the large volumes of complex data that will be generated by the SMCL and the MIC. This integrative computational hub will link together the two key biomedical platforms and provide the principal University portal for clinical "pull through" of stratified medicine to and from individual patient records in the NHS.
These investments will leverage international research strengths in Cambridge and are aligned with major investments by Cambridge University Health Partners.

Planned Impact

No impact summary is required for applications to the Clinical Research Infrastructure call.

Publications

10 25 50

publication icon
Bevan Jones WR (2016) [18F]AV-1451 PET in behavioral variant frontotemporal dementia due to MAPT mutation. in Annals of clinical and translational neurology

publication icon
Bevan-Jones RW (2018) [18F]AV-1451 binding is increased in frontotemporal dementia due to C9orf72 expansion. in Annals of clinical and translational neurology

 
Description (Prof James Rowe, Cambridge PI) Dementias Platform UK (part 1)
Amount £1,200,000 (GBP)
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 06/2017 
End 05/2021
 
Description (Prof James Rowe, Cambridge co-applicant) Dementias Platform UK (part 2)
Amount £7,500,000 (GBP)
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 01/2021 
End 12/2025
 
Description BBSRC iCASE
Amount £105,000 (GBP)
Organisation Biotechnology and Biological Sciences Research Council (BBSRC) 
Sector Public
Country United Kingdom
Start 09/2018 
End 09/2022
 
Description BBSRC iCASE studentship partnered with MedImmune (Sam Galvin)
Amount £95,196 (GBP)
Organisation Biotechnology and Biological Sciences Research Council (BBSRC) 
Sector Public
Country United Kingdom
Start 09/2016 
End 09/2020
 
Description Bridging the gap: biophysical models of human frontotemporal lobar degeneration
Amount £2,025,694 (GBP)
Funding ID 220258/Z/20/Z 
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 03/2021 
End 03/2026
 
Description Cambridge Centre for Parkinsons Plus
Amount $20,000,000 (USD)
Organisation University of Cambridge 
Sector Academic/University
Country United Kingdom
Start 02/2018 
End 03/2022
 
Description Covid plasma LC-MS analysis
Amount £4,875 (GBP)
Organisation Addenbrooke's Charitable Trust (ACT) 
Sector Charity/Non Profit
Country United Kingdom
Start 04/2020 
End 07/2020
 
Description Dementia Platform UK
Amount £2,677,560 (GBP)
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 09/2014 
End 03/2015
 
Description Liver disease peptidomics and proteomics
Amount £24,350 (GBP)
Organisation National Institute for Health Research 
Department NIHR Biomedical Research Centre
Sector Public
Country United Kingdom
Start 02/2020 
End 12/2020
 
Description MRC Equip - World Class Labs award 2022/23
Amount £503,852 (GBP)
Funding ID MC_PC_MR/X012417/1 
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 03/2023 
 
Description MRC Equip - World Class Labs award 2022/23 - host contribution
Amount £125,963 (GBP)
Organisation University of Cambridge 
Sector Academic/University
Country United Kingdom
Start 03/2023 
 
Description MRC MDU
Amount £1,500,000 (GBP)
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 03/2018 
End 03/2023
 
Description Medimmune grant
Amount £272,857 (GBP)
Organisation AstraZeneca 
Department MedImmune
Sector Private
Country United Kingdom
Start 05/2015 
End 08/2017
 
Description NIHR Cambridge Biomedical Research Centre
Amount £112,000,000 (GBP)
Organisation National Institute for Health Research 
Sector Public
Country United Kingdom
Start 03/2017 
End 03/2022
 
Description PET++: Improving Localisation, Diagnosis and Quantification in Clinical and Medical PET Imaging with Randomised Optimisation
Amount £821,421 (GBP)
Funding ID EP/S026045/1 
Organisation Engineering and Physical Sciences Research Council (EPSRC) 
Sector Public
Country United Kingdom
Start 08/2019 
End 08/2023
 
Description Peptidomics of gestational diabetes
Amount £3,400 (GBP)
Organisation University of Cambridge 
Sector Academic/University
Country United Kingdom
Start 05/2020 
End 03/2021
 
Description PhD in Clinical Biochemistry
Amount £100,000 (GBP)
Funding ID 2430172 
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 09/2020 
End 03/2024
 
Description Restoring brain function: from cortical microcircuits to complex behaviours in neurodegenerative disease.
Amount £1,908,236 (GBP)
Funding ID 103838/Z/14/Z 
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 12/2014 
End 05/2021
 
Description Targeting the gut in metabolic disease
Amount £2,381,203 (GBP)
Funding ID 220271/Z/20/Z 
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 07/2020 
End 07/2025
 
Title Alteration of the plasma peptidome of gastrectomised patients during an OGTT 
Description Performing gastric bypass surgery on patients severely changes their gut hormone response to glucose. The plasma concentrations of Insulin and a number of associated incretin peptides are significantly raised shortly after ingestion of glucose. Typically the plasma concentrations of these peptides are monitored using immunoassays. A simple and high throughput plasma peptidomics approach was used to simulatneously monitor a large number of these peptides. Comparison of gastresctomised and control individuals showed significant increases of insulin, glucagon gene products, PYY and neurotensin. 
Type Of Material Database/Collection of data 
Year Produced 2020 
Provided To Others? Yes  
Impact open dataset 
URL https://www.ebi.ac.uk/pride/archive/projects/PXD016690
 
Title Chinese Color Nest Project (CCNP) 
Description CCNP takes its pilot stage (2013 - 2022) of the first ten-year. It aims at establishing protocols on the Chinese normative brain development trajectories across the human lifespan. It implements a structured multi-cohort longitudinal design (or accelerated longitudinal design), which is particularly viable for lifespan trajectory studies, and optimal for recoverable missing data. The CCNP pilot comprises three connected components: developing CCNP (devCCNP, baseline age = 6-18 years, 12 age cohorts, 3 waves, interval = 15 months), maturing CCNP (matCCNP, baseline age = 18-60 years, 14 age cohorts, 3 waves, interval = 39 months) and ageing CCNP (ageCCNP, baseline age = 60-84 years, 12 age cohorts, 3 waves, interval = 27 months). The developmental component of CCNP (devCCNP, 2013-2022), also known as "Growing Up in China", a ten-year's pilot stage of CCNP, has established follow-up cohorts in Chongqing (,CKG, Southwest China) and Beijing (PEK, Northeast China). It is an ongoing project focused on longitudinal developmental research as creating and sharing a large-scale multimodal dataset for typically developing Chinese children and adolescents (ages 6.0-17.9 at enrollment) carried out in both school- and community-based samples. The devCCNP houses longitudinal data about demographics, biophysical measures, psychological and behavioral assessments, cognitive phenotyping, ocular-tracking, as well as multimodal magnetic resonance imaging (MRI) of brain's resting and naturalistic viewing function, diffusion structure and morphometry. With the collection of longitudinal structured images and psychobehavioral samples from school-age children and adolescents in multiple cohorts, devCCNP has constructed a full school-age brain template and its growth curve reference for Han Chinese which demonstrated the difference in brain development between Chinese and American school-aged children.To access the data, investigators must complete the application file Data Use Agreement on CCNP (DUA-CCNP) at http://deepneuro.bnu.edu.cn/?p=163 and have it reviewed and approved by the Chinese Color Nest Consortium (CCNC). All terms specified by the DUA-CCNP must be complied with. Meanwhile, the baseline CKG Sample on brain imaging are available to researchers via the International Data-sharing Neuroimaging Initiative (INDI) through the Consortium for Reliability and Reproducibility (CoRR). More information about CCNP can be found at: http://deepneuro.bnu.edu.cn/?p=163 or https://github.com/zuoxinian/CCNP. Requests for further information and collaboration are encouraged and considered by the CCNC, and please read the Data Use Agreement and contact us via deepneuro@bnu.edu.cn. The CCNP data will be fully available to the research community when acquisition is completed for the pilot CCNP. At this stage, the CCNP data are only available to researchers and collaborators of CCNC. 
Type Of Material Database/Collection of data 
Year Produced 2023 
Provided To Others? Yes  
URL https://www.scidb.cn/en/detail?dataSetId=c81f0e90a51b4cfca348ce4da6ca734e
 
Title Peptidomics of sorted enteroendocrine cells from human organoids 
Description A human organoid culture system was set up to grow enteroendocrine cells with a venus labeled on the glucagon gene promoter sequence. This enabled the sorting of glucagon gene positive cells from negative cells, thereby enabling the enrichment of glucagon producing cells for study. Both Venus positive and venus negative cell populations were collected and their peptidome was assessed using nano LC-MS/MS 
Type Of Material Database/Collection of data 
Year Produced 2020 
Provided To Others? Yes  
Impact open data 
URL https://www.ebi.ac.uk/pride/archive/projects/PXD017825
 
Title Peptidomics profiling of biopsies from the human jejunum before and after gastrectomy 
Description Profiling of the human jejunum peptidome before and after total gastrectomy. The study compares the peptidome of jejunum using intact mass spectrometry and database searching. These peptides included most gut hormones including proglucagon derived peptides, PYY, GIP, Motilin somatostatin and neurotensin amongst others. 
Type Of Material Database/Collection of data 
Year Produced 2019 
Provided To Others? Yes  
Impact open dataset 
URL https://www.ebi.ac.uk/pride/archive/projects/PXD011498
 
Title Peptidomics profiling of human intestine 
Description The aim of the project is to generate a peptidomics map of gut hormone peptides along the gastrointestinal tract, starting with the stomach and including the duodenum, jejunum, ileum, ascending colon, sigmoid colon and rectum. The tissues would be collected after surgery and the peptide fraction extracted and anlysed by nano LC-MS to identify what peptide hormones are present. These data will then be used to compare against the human transcriptome, and also for comparison against equivent peptides from murine intestinal extracts. 
Type Of Material Database/Collection of data 
Year Produced 2019 
Provided To Others? Yes  
Impact open dataset 
URL https://www.ebi.ac.uk/pride/archive/projects/PXD009788
 
Title Peptidomics profiling of murine intestine 
Description The aim of the project is to generate a peptidomics map of gut hormone peptides along the gastrointestinal tract, starting with the stomach and including the duodenum, jejunum, ileum, colon and rectum. The tissues would be collected after surgery and the peptide fraction extracted and anlysed by nano LC-MS to identify what peptide hormones are present. These data will then be used to compare against the murine transcriptome, and also for comparison against equivent peptides from human intestinal extracts. 
Type Of Material Database/Collection of data 
Year Produced 2019 
Provided To Others? Yes  
Impact open dataset 
URL https://www.ebi.ac.uk/pride/archive/projects/PXD009796
 
Title Peptidomics profiling of the murine gut after vertical sleeve gastrectomy 
Description Profiling of the murine peptidome along the gastrointestinal tract and pancreas in vertical sleeve gastrectomy and sham operated mice. The study compares the peptidome of various portions of the GI tract using intact mass spectrometry and database searching. These peptides included most gut hormones including proglucagon derived peptides, PYY, GIP, somatostatin, neurotensin amongst others. 
Type Of Material Database/Collection of data 
Year Produced 2019 
Provided To Others? Yes  
Impact open dataset 
URL https://www.ebi.ac.uk/pride/archive/projects/PXD011455
 
Title developing Chinese Color Nest Project (devCCNP) Lite 
Description CCNP takes its pilot stage (2013 - 2022) of the first ten-year. It aims at establishing protocols on the Chinese normative brain development trajectories across the human lifespan. It implements a structured multi-cohort longitudinal design (or accelerated longitudinal design), which is particularly viable for lifespan trajectory studies, and optimal for recoverable missing data. The CCNP pilot comprises three connected components: developing CCNP (devCCNP, baseline age = 6-18 years, 12 age cohorts, 3 waves, interval = 15 months), maturing CCNP (matCCNP, baseline age = 18-60 years, 14 age cohorts, 3 waves, interval = 39 months) and ageing CCNP (ageCCNP, baseline age = 60-84 years, 12 age cohorts, 3 waves, interval = 27 months). The developmental component of CCNP (devCCNP, 2013-2022), also known as "Growing Up in China", a ten-year's pilot stage of CCNP, has established follow-up cohorts in Chongqing (CKG, Southwest China) and Beijing (PEK, Northeast China). It is an ongoing project focused on longitudinal developmental research as creating and sharing a large-scale multimodal dataset for typically developing Chinese children and adolescents (ages 6.0-17.9 at enrollment) carried out in both school- and community-based samples. The devCCNP houses longitudinal data about demographics, biophysical measures, psychological and behavioral assessments, cognitive phenotyping, ocular-tracking, as well as multimodal magnetic resonance imaging (MRI) of brain's resting and naturalistic viewing function, diffusion structure and morphometry. With the collection of longitudinal structured images and psychobehavioral samples from school-age children and adolescents in multiple cohorts, devCCNP has constructed a full school-age brain template and its growth curve reference for Han Chinese which demonstrated the difference in brain development between Chinese and American school-aged children.*This dataset contains only T1-weighted MRI, Resting-state fMRI and Diffusion Tensor MRI data of devCCNP.To access the devCCNP Lite data, investigators must complete the application file Data Use Agreement on CCNP (DUA-CCNP) at http://deepneuro.bnu.edu.cn/?p=163 and have it reviewed and approved by the Chinese Color Nest Consortium (CCNC). All terms specified by the DUA-CCNP must be complied with. Meanwhile, the baseline CKG Sample on brain imaging are available to researchers via the International Data-sharing Neuroimaging Initiative (INDI) through the Consortium for Reliability and Reproducibility (CoRR). More information about CCNP can be found at: http://deepneuro.bnu.edu.cn/?p=163 or https://github.com/zuoxinian/CCNP. Requests for further information and collaboration are encouraged and considered by the CCNC, and please read the Data Use Agreement and contact us via deepneuro@bnu.edu.cn. 
Type Of Material Database/Collection of data 
Year Produced 2024 
Provided To Others? Yes  
URL https://www.scidb.cn/en/detail?dataSetId=40493741c1e746f8a11f0b96cb7a4e1f
 
Description Collaboration with University of Edinburgh on Inflammation in dementia 
Organisation University of Edinburgh
Country United Kingdom 
Sector Academic/University 
PI Contribution Intellectual expertise and collaborative links. A collaboration between University of Cambridge and University of Edinburgh linking Dementia Research Investigators with BRC and DPUK translational research programs.
Collaborator Contribution Intellectual expertise and collaborative links. A collaboration between University of Cambridge and University of Edinburgh linking Dementia Research Investigators with BRC and DPUK translational research programs.
Impact Providing direction and collaboration between dementia research investigators with BRC and DPUK translational research programs.
Start Year 2021
 
Description GE MRC CRI PET/MRI 
Organisation GE Healthcare Limited
Country United Kingdom 
Sector Academic/University 
PI Contribution The University, as part of the MRC Dementia Platform UK, will enable access to the new PET/MRI system and will share expertise and software for advanced image acquisition with the GE team.
Collaborator Contribution GE have provided substantial cash contribution in the form of major discounts on list price of the PET/MRI system and related equipment, amounting to about 46% of list price. GE will additionally provide substantial in-kind support including: scientific and technical staff working on-site to help the University commissioning the new PET/MRI system and optimising its performance as part of the MRC Dementia Platform UK; PhD studentship; image analysis software; funds for start-up research projects on the new scanner.
Impact No outputs yet
Start Year 2015
 
Description LGC peptidomics 
Organisation LGC Ltd
Country Global 
Sector Private 
PI Contribution Supporting a BBSRC iCASE studentship
Collaborator Contribution Analysis and training
Impact One publication to date
Start Year 2017
 
Description Mercodia assay validation 
Organisation Mercodia AB
Country Sweden 
Sector Private 
PI Contribution Mass spec analysis to validate Mercodia's glucagon assay. Measurement of patient samples using glucagon and glicentin assays to establish the cause of assay cross reactivity
Collaborator Contribution Provision of assays and suggestions for protocol changes to remove cross-reactivity
Impact Mercodia published a white paper outlining the collaboration and how it has impacted on the use of the glucagon assay
Start Year 2018
 
Description ROWE GROUP: Dr M Malpetti Collaboration with Ludwig Maximilian University "TSPO PET in Tauopathies" 
Organisation Ludwig Maximilian University of Munich (LMU Munich)
Country Germany 
Sector Academic/University 
PI Contribution Data analysis and expertise.
Collaborator Contribution Data analysis and expertise.
Impact Working on data collection and analysis with a view to future publication(s).
Start Year 2021
 
Description ROWE Group: Dr M Malpetti "Tau-PET and domain-specific cognitive decline in Alzheimer's disease" 
Organisation University of California, San Francisco
Country United States 
Sector Academic/University 
PI Contribution Data generation and analysis
Collaborator Contribution Data generation and analysis
Impact Planned publications from collaboration.
Start Year 2021
 
Description Siemens MRC CRI SKYRA 
Organisation Siemens AG
Department Siemens Magnet Technology
Country United Kingdom 
Sector Private 
PI Contribution The University will provide access to Siemens to the 3T SKYRA system and will release prototype pulse sequences for MRI data acquisition.
Collaborator Contribution Siemens will commit technical and scientific staff to work alongside the University commissioning the new 3T SKYRA upgrade and optimising its performance.
Impact TBC
Start Year 2015
 
Description Siemens MRC CRI Skyra 
Organisation Siemens Healthcare
Country Germany 
Sector Private 
PI Contribution The University of Cambridge in general and the Wolfson Brain Imaging Centre in particular have long-standing research collaboration agreements with Siemens. The University provides access to equipment, software and clinical data in support of the collaborative partnership with Siemens.
Collaborator Contribution Siemens provided a substantial discount on the list price of SKYRA 3T upgrade.
Impact No outputs yet from SKYRA upgrade.
Start Year 2015
 
Description 13th annual Biomarkers Congress 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Industry/Business
Results and Impact An industrial congress bringing together a variety of industrial technologies for the measurement of biomarkers
Year(s) Of Engagement Activity 2018
 
Description BBSRC symposium 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Postgraduate students
Results and Impact RF poster: Mass spectrometry vs immunoassay
SG poster: Identification and in vivo characterisation of novel gut-derived peptides
Year(s) Of Engagement Activity 2020
 
Description Cambridge City Council holiday club EM 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Public/other audiences
Results and Impact Science activities at Cambridge City Council drop-in holiday club for families
Year(s) Of Engagement Activity 2021
 
Description Cambridgeshire Girlguiding Girls in STEM event 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Other audiences
Results and Impact Cambridgeshire Girlguiding Girls in STEM event
Year(s) Of Engagement Activity 2020
 
Description Cancer cachexia network, invited speaker 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Professional Practitioners
Results and Impact Talk entitled "Plasma peptide LC-MS/MS analysis: How to find needles in haystacks"
Year(s) Of Engagement Activity 2023
 
Description DG Poster at EASD study group 2017 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact "Developing 2D organoid cultures to study intracellular signalling in enteroendocrine cells"
Year(s) Of Engagement Activity 2017
 
Description DG Poster at EASD study group 2019 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact DG. Poster at Incretin Study Group: "Modelling human enteroendocrine cells using adult intestinal organoids"
Year(s) Of Engagement Activity 2019
 
Description Danish diabetes and endocrine academy, symposium "Translating Biomarkers into Clinical Endocrinology: Analytes, Assays & Algorithms" 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Invited speaker, talk entitled "Diagnostic assays for peptide hormones: Mass spectrometry or Immunoassay based?"
Year(s) Of Engagement Activity 2023
 
Description EM Talk at Society for Endocrinology conference 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Talk at Society for Endocrinology conference
Year(s) Of Engagement Activity 2021
 
Description EM: Danish Diabetes Academy 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Postgraduate students
Results and Impact Poster presentation at Danish Diabetes academy - "Characterising stimulus-secretion coupling of the gut hormone motilin in human duodenal organoids"
Year(s) Of Engagement Activity 2020
 
Description EM: Physiology of Obesity: From Mechanisms to Medicine 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Postgraduate students
Results and Impact Hormonal Regulation of Gut and Pancreas Physiology" - online webinar as part of Journal of Physiology 'Physiology of Obesity: From Mechanisms to Medicine' series
Year(s) Of Engagement Activity 2020
 
Description FG Foster talk 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Postgraduate students
Results and Impact FG gave invited lecture in the Department of Physiology, Development and Neuroscience at University of Cambridge.
Year(s) Of Engagement Activity 2021
 
Description FG invited speaker at Keystone conference: Interconnection between the Gut, Brain and Microbiome for Metabolic Disease 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Triggered questions, collaborations and discussion with industry
Year(s) Of Engagement Activity 2022
 
Description FG invited speaker at Metabolism in Action conference in Copenhagen 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Triggered questions and potential collaborations
Year(s) Of Engagement Activity 2022
URL https://cbmr.ku.dk/metabolism-in-action/
 
Description FG invited speaker at symposium on 100 years of Glucagon 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Invited talk at this symposium
Year(s) Of Engagement Activity 2022
URL http://glucagonconference.com/
 
Description FG invited talk at 7th International Conference on Food Digestion, Cork 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Invited speaker at this conference on food digestion.
Year(s) Of Engagement Activity 2022
URL http://www.icfd2022.com
 
Description FG invited talk at International scientific symposium - Gut / brain axis and regulation of food intake, organized by SFNCM/INRAE 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Invited talk at this symposium. Delivered virtually due to travel difficulties. Inspired questions from the audience
Year(s) Of Engagement Activity 2022
 
Description FG talk at MRC-DTP symposium 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Postgraduate students
Results and Impact FG gave invited lecture at the annual symposium of the MRC-DTP students in Cambridge.
Year(s) Of Engagement Activity 2021
 
Description FG talk at Milner Therapeutics Institute 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Industry/Business
Results and Impact FG gave invited lecture to the Milner Institute, which includes industrial audiences from around the world. The talk triggered many interesting questions.
Year(s) Of Engagement Activity 2021
 
Description FR. presentation at Danish Diabetes Academy Winter School for postdoctoral researchers, at Higuerõn Hotel in Malaga/Spain 2019 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact "Incretins along the gut-pancreas-brain axis".
Year(s) Of Engagement Activity 2019
 
Description FR: Mercodia Diagnostics, Uppsala. Invited speaker 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Industry/Business
Results and Impact Invited to talk to Mercodia about how our mass spec analysis methods complement their immunoassay development
Year(s) Of Engagement Activity 2019
 
Description Interactive presentation of MRC CRI funded MRI technology for general public 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Public/other audiences
Results and Impact Cambridge Brainfest was a major public engagement event organised by Cambridge Neuroscience, which attracted 3000 visitors to the Corn Exchange in central Cambridge for two days of interactive exhibitions, short talks and other events. There were multiple exhibits and talks which featured the high performance MRI equipment funded by this award.
Year(s) Of Engagement Activity 2017
URL https://www.neuroscience.cam.ac.uk/brainfest
 
Description London Biological Mass Spectrometry Discussion Group 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Professional Practitioners
Results and Impact Invited speaker, talk entitled " Peptidomics: The unexplored space between metabolomics and proteomics"
Year(s) Of Engagement Activity 2023
 
Description London Biological Mass Spectrometry Discussion Group. 2024 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Invited speaker, talk entitled "The identification of GDF15 as the cause of morning sickness in pregnancy: how did mass spectrometry contribute?".
Year(s) Of Engagement Activity 2024
 
Description Movement Disorder Society International Conference 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Gave a talk titled UHF 7T imaging to Progressive supranuclear palsy subgroup.
Year(s) Of Engagement Activity 2021
 
Description PL. Poster at Incretin Study Group 2017 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact "SCFAs increase PYY but not GLP1 production in human L-cells "
Year(s) Of Engagement Activity 2017
 
Description PL. Talk at Incretin Study Group 2019 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact PL. Talk at Incretin Study Group. "Peptidomics to study enteroendocrine cells after bariatric surgery"
Year(s) Of Engagement Activity 2019
 
Description Prof. James N Rowe: Brain Bus Initiative by MRC-CBU Researchers 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Schools
Results and Impact The purpose of the BrainBus project is to provide a pivotal outreach experience to underprivileged children, exposing them to subjects, careers and role models which they would not otherwise access.
Year(s) Of Engagement Activity 2021
URL https://www.mrc-cbu.cam.ac.uk/brain-bus/
 
Description REF Poster at SymBLS 2019 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Postgraduate students
Results and Impact Size Exclusion Chromatography for Measuring Free and Antibody-bound Insulin in Hiratas Patients
Year(s) Of Engagement Activity 2019
 
Description REF. Poster at DMDG open meeting 2019 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Industry/Business
Results and Impact "Size Exclusion Chromatography for Measuring Free and Antibody-bound Insulin in Hiratas Patients"
Year(s) Of Engagement Activity 2019
 
Description REF. Poster at EASD incretin study group 2019 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact REF poster at EASD study group "A multiplex method for quantifying gut hormone peptides using Mass Spectrometry"
Year(s) Of Engagement Activity 2019
 
Description REF. Poster at REID Bioanalytical Forum 2019 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Industry/Business
Results and Impact Immunoassay vs Mass Spectrometry -Measuring insulin and insulin analogues in human plasma
Year(s) Of Engagement Activity 2019
 
Description RF: Murray Edwards Graduate Symposium 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Postgraduate students
Results and Impact RF: Measuring insulin and insulin analogues in human plasma
Year(s) Of Engagement Activity 2021
 
Description RGK Incretin 2022 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact poster presentation at Incretin 2022. Lots of interest
Year(s) Of Engagement Activity 2022
 
Description RGK Invited lecture on Mass Spectrometric analysis of Insulin at Anglian Ruskin University. Cambridge, UK 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Undergraduate students
Results and Impact 1st March 2023. Invited lecture on Mass Spectrometric analysis of Insulin at Anglian Ruskin University. Cambridge, UK
Audience: Staff and students
Size: ~100 participants
Year(s) Of Engagement Activity 2022
 
Description RGK Invited speaker at Reid Bioanalytical Forum. Cambourne, Cambridgeshire, UK 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Industry/Business
Results and Impact 5Th September 2022. Invited speaker at Reid Bioanalytical Forum. Cambourne, Cambridgeshire, UK
Audience: Mainly bioanalytical scientists from industry
Size: ~100 participants
Year(s) Of Engagement Activity 2022
 
Description RGK Invited speaker at the Peptidomics Symposium. University of Copenhagen, Denmark 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact 23rd August 2022. Invited speaker at the Peptidomics Symposium. University of Copenhagen, Denmark
Audience: Academics and Clinicians
Size: ~150 participants
Outcome: Was invited to talk at the 2023 Danish Diabetes and Endocrine Academy conference
Year(s) Of Engagement Activity 2022
 
Description RGK London Proteomics Discussion Group. London, UK 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Audience: Academic and industry researchers in the proteomics field
Size: ~50 participants
Outcome: Was invited to talk at the 2022 Reid Bioanalytical Forum
Year(s) Of Engagement Activity 2022
 
Description RGK Proteomics Method Forum 2020 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Industry/Business
Results and Impact Peptidomics: bridging the space between large and small molecule mass spectrometry
Year(s) Of Engagement Activity 2020
 
Description RGK. American Society for Mass Spectrometry (ASMS) 2019 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Industry/Business
Results and Impact Waters user group meeting, presentation:
"LC-MS analysis of plasma from patients with insulin autoimmune syndrome"
Waters MS focused user meeting (Pharmaceutical track)
Outcome: Video of talk available on Waters website, video interview on Select Science website, as well as an in-lab video interview.
Year(s) Of Engagement Activity 2019
 
Description RGK. Poster at EASD incretin study group 2017 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact "Development of a rapid extraction method for the analysis of gut peptide hormones by LC-MS/MS"
Year(s) Of Engagement Activity 2017
 
Description RGK. Poster at EASD incretin study group 2019 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Poster at EASD incretin study group: "Proglucagon peptide analysis - will the real peptide please stand up!"
Year(s) Of Engagement Activity 2019
 
Description RGK. Reid Bioanalytical Forum 2019 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Industry/Business
Results and Impact "LC-MS analysis of plasma from patients with insulin autoimmune syndrome"
Meeting focussing on broad bioanalytical approaches for wide range of analytes
Outcome: Video interview by Bionalaysis zone, available on their website
Year(s) Of Engagement Activity 2019
 
Description RGK. Waters UK and Ireland Clinical User Meeting 2019 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Industry/Business
Results and Impact Waters UK and Ireland Clinical User Meeting 2019
"LCMS Analysis of Proinsulin Derived Peptides"
Waters meeting for users of MS systems in clinical environments
Year(s) Of Engagement Activity 2019
 
Description RGK: Select Science Clinical Science Symposium 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Plasma peptidomics - an untapped resource for biomarker analysis."
Year(s) Of Engagement Activity 2020
 
Description SG. Poster at EASD incretin study group 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact SG. Poster at EASD study group. "Characterisation of novel gut-derived peptides in vivo and in vitro"
Year(s) Of Engagement Activity 2019
 
Description SG. Poster at EASD incretin study group 2017 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact LC-MS based detection of insulin-like peptide 5 in primary colonic cultures
Year(s) Of Engagement Activity 2017
 
Description Talk by Dr N Holland - ROWE Group at Cambrige Imaging Festival 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Professional Practitioners
Results and Impact Talk title "Synaptic imaging in dementia and neurodegenerative disease"
Year(s) Of Engagement Activity 2021
 
Description Talk by Prof Rowe at Cambridge Imaging Festival 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Professional Practitioners
Results and Impact Talk given at Cambridge Imaging Festival titled "New directions in dementia imaging"
Year(s) Of Engagement Activity 2021
 
Description Tutor on the Drug Metabolism and Discussion Group (DMDG) large molecule bioanalysis course 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Industry/Business
Results and Impact Richard Kay was Tutor on the Drug Metabolism and Discussion Group (DMDG) large molecule bioanalysis course. A three day course held at Loughborough University, focussed on the dissemination of knowledge for developing bioanalytical methodologies for large molecule analytes.
Year(s) Of Engagement Activity 2017
 
Description Tutor on the Drug Metabolism and Discussion Group (DMDG) large molecule bioanalysis course 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Industry/Business
Results and Impact Richard Kay was Tutor on the Drug Metabolism and Discussion Group (DMDG) large molecule bioanalysis course. A three day course held at Loughborough University, focussed on the dissemination of knowledge for developing bioanalytical methodologies for large molecule analytes.
Year(s) Of Engagement Activity 2017
 
Description University of Cambridge & AZ science symposium 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Industry/Business
Results and Impact SG Presentation: Utilising LC/MS to identify novel bioactive gut-derived peptides and peptidomic differences in type 2 diabetic human islets
FG Panel discussion
Year(s) Of Engagement Activity 2020
 
Description Workshop Chair Dr M Malpetti (Rowe Group): Combining imaging modalities with machine learning 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Workshop chair of "Combining imaging modalities with machine learning" session at ERC DEMON workshop 2021
Year(s) Of Engagement Activity 2021